Literature DB >> 16706637

Application of I(125) brachytherapy combined artificial joint prosthesis in malignant osteo- and soft-tissue sarcoma.

D F Li1, Q Cui, Q Wang, H Su, W J Zhang, P Zhang, J Zhou, J H Sui, Yanjun J Zeng.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the brachytherapy effectiveness of I(125) seeds combined with artificial prosthesis in malignant sarcoma therapy.
METHODS: The combination of I(125) seeds and artificial prosthesis was implanted to replace tumor section for three clinical cases-2 malignant osteosarcoma patients and 1 malignant soft-tissue tumor patient- through the direct operation.
RESULTS: Approximately 14-18 months after the operation, the results of our post-operational investigation showed that the tumor tissues of 3 patients had been completely removed. The limb functions recovered well. The brachytherapy of the combination of I(125) seeds and artificial prosthesis in malignant tumor improved the curative effect. No tumor existed, and no infection occurred.
CONCLUSIONS: It was demonstrated that this method was safe and easy. No side-effect was observed after the implantation of I(125) seeds. The brachytherapy was proven to be a potential method for patients who were at high risk to recrudesce the malignant osteosarcoma of tumors after the tumor excision.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16706637     DOI: 10.1089/cbr.2006.21.167

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  2 in total

1.  Comprehensive treatment based on intra-arterial chemotherapy for distal femur neoplasms.

Authors:  Cheng Liu; Qiu Cui; Cuili Shu; Jun Guo; Dingfeng Li
Journal:  Pathol Oncol Res       Date:  2013-02-17       Impact factor: 3.201

2.  Permanent interstitial 125I seed implantation as a salvage therapy for pediatric recurrent or metastatic soft tissue sarcoma after multidisciplinary treatment.

Authors:  Lihong Yao; Junjie Wang; Yuliang Jiang; Jinna Li; Lei Lin; Weiqiang Ran; Chen Liu
Journal:  World J Surg Oncol       Date:  2015-12-15       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.